Chuanji Wu, Peiyang Yuan, Xuemei Qiu, Dan Liu, Yiming Xu, Yanxuan Xiao, Shuting Zhou, Zhenyu Zhang, Shuning Cai, Wei Ding, Xiaoping Xu, Feifei Hou, Lu Jiang
{"title":"Short-Term Dietary Caffeine Intake for Alleviating Symptoms of Burning Mouth Syndrome: A Randomised Controlled Comparison With Alpha-Lipoic Acid.","authors":"Chuanji Wu, Peiyang Yuan, Xuemei Qiu, Dan Liu, Yiming Xu, Yanxuan Xiao, Shuting Zhou, Zhenyu Zhang, Shuning Cai, Wei Ding, Xiaoping Xu, Feifei Hou, Lu Jiang","doi":"10.1111/joor.13957","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study investigates whether daily supplementation of 120-150 mg of caffeine can relieve symptoms of Burning Mouth Syndrome (BMS) compared to alpha-lipoic acid (ALA) and a control group.</p><p><strong>Methods: </strong>In this randomised controlled trial, 118 BMS patients were divided into three groups: caffeine, ALA, and control. The caffeine group received 120-150 mg of caffeine daily, the ALA group received 200 mg of ALA three times daily, and the control group received no interventions. Symptom relief was assessed over 2 weeks using the Visual Analog Scale (VAS), with subgroup analyses based on symptom subtypes, disease duration, symptom sites, and characteristics.</p><p><strong>Results: </strong>The VAS of BMS patients in the caffeine and ALA groups exhibited significant reductions (p < 0.0005). The caffeine group exhibited a 65.1% symptom relief rate compared to 46.5% in the ALA group and 12.5% in the control group. Significant differences in symptom relief were noted between the caffeine and control groups (p < 0.0005) and between the ALA and control groups (p = 0.0032). No significant difference was observed between the caffeine and ALA groups (p = 0.084). Type I BMS patients in the caffeine group showed greater symptom relief than those in the ALA group (p = 0.026).</p><p><strong>Conclusions: </strong>Both caffeine and ALA effectively treated BMS, with caffeine showing higher efficacy in Type I patients. Treatments were well-tolerated with minimal adverse effects, suggesting caffeine and ALA as promising treatments for BMS, warranting further research on their long-term effects and mechanisms of action. [The study was registered on ClinicalTrials.gov (Identification No. NCT06195137).].</p>","PeriodicalId":16605,"journal":{"name":"Journal of oral rehabilitation","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of oral rehabilitation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/joor.13957","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study investigates whether daily supplementation of 120-150 mg of caffeine can relieve symptoms of Burning Mouth Syndrome (BMS) compared to alpha-lipoic acid (ALA) and a control group.
Methods: In this randomised controlled trial, 118 BMS patients were divided into three groups: caffeine, ALA, and control. The caffeine group received 120-150 mg of caffeine daily, the ALA group received 200 mg of ALA three times daily, and the control group received no interventions. Symptom relief was assessed over 2 weeks using the Visual Analog Scale (VAS), with subgroup analyses based on symptom subtypes, disease duration, symptom sites, and characteristics.
Results: The VAS of BMS patients in the caffeine and ALA groups exhibited significant reductions (p < 0.0005). The caffeine group exhibited a 65.1% symptom relief rate compared to 46.5% in the ALA group and 12.5% in the control group. Significant differences in symptom relief were noted between the caffeine and control groups (p < 0.0005) and between the ALA and control groups (p = 0.0032). No significant difference was observed between the caffeine and ALA groups (p = 0.084). Type I BMS patients in the caffeine group showed greater symptom relief than those in the ALA group (p = 0.026).
Conclusions: Both caffeine and ALA effectively treated BMS, with caffeine showing higher efficacy in Type I patients. Treatments were well-tolerated with minimal adverse effects, suggesting caffeine and ALA as promising treatments for BMS, warranting further research on their long-term effects and mechanisms of action. [The study was registered on ClinicalTrials.gov (Identification No. NCT06195137).].
期刊介绍：
Journal of Oral Rehabilitation aims to be the most prestigious journal of dental research within all aspects of oral rehabilitation and applied oral physiology. It covers all diagnostic and clinical management aspects necessary to re-establish a subjective and objective harmonious oral function.
Oral rehabilitation may become necessary as a result of developmental or acquired disturbances in the orofacial region, orofacial traumas, or a variety of dental and oral diseases (primarily dental caries and periodontal diseases) and orofacial pain conditions. As such, oral rehabilitation in the twenty-first century is a matter of skilful diagnosis and minimal, appropriate intervention, the nature of which is intimately linked to a profound knowledge of oral physiology, oral biology, and dental and oral pathology.
The scientific content of the journal therefore strives to reflect the best of evidence-based clinical dentistry. Modern clinical management should be based on solid scientific evidence gathered about diagnostic procedures and the properties and efficacy of the chosen intervention (e.g. material science, biological, toxicological, pharmacological or psychological aspects). The content of the journal also reflects documentation of the possible side-effects of rehabilitation, and includes prognostic perspectives of the treatment modalities chosen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
